drugset
drugset / Trial / NCT00191269

Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen

NCT00191269 ↗

Phase 2 Completed 68 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To investigate efficacy, safety and PK of GEM monotherapy after prior chemotherapy with anthracycline and taxane regimen for patients with metastatic breast cancer

Timeline

Start
2005-06
Primary completion
2008-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1250 mg/m2 Intravenous

Indications

breast cancer